标题
The Cysteinome of Protein Kinases as a Target in Drug Development
作者
关键词
-
出版物
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 57, Issue 16, Pages 4372-4385
出版商
Wiley
发表日期
2017-10-10
DOI
10.1002/anie.201707875
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping
- (2017) Michael Juchum et al. JOURNAL OF MEDICINAL CHEMISTRY
- Determining Cysteines Available for Covalent Inhibition Across the Human Kinome
- (2017) Zheng Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3
- (2017) Felix Muth et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
- (2017) Atli Thorarensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site
- (2017) Marcel Günther et al. JOURNAL OF MEDICINAL CHEMISTRY
- Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes
- (2017) Qian Zhao et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
- (2017) Antonio Passaro et al. PHARMACOLOGICAL RESEARCH
- Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase
- (2016) Francesco Ansideri et al. ANALYTICAL BIOCHEMISTRY
- Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant
- (2016) Marcel Günther et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Targeted Covalent Inhibitors for Drug Design
- (2016) Thomas A. Baillie ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations
- (2016) Weiguo Zhang et al. CANCER RESEARCH
- Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer
- (2016) Sean Khozin et al. CLINICAL CANCER RESEARCH
- A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma
- (2016) Daniel W. Bowles et al. Clinical Colorectal Cancer
- Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
- (2016) Paul A. Jackson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3
- (2016) Alvin Kung et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Proteome-wide covalent ligand discovery in native biological systems
- (2016) Keriann M. Backus et al. NATURE
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- (2016) Yong Jia et al. NATURE
- Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
- (2016) Tinghu Zhang et al. Nature Chemical Biology
- Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling
- (2016) Geoffrey A Smith et al. Nature Chemical Biology
- I-SPY 2 — A Glimpse of the Future of Phase 2 Drug Development?
- (2016) David Harrington et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of small molecules targeting the pseudokinase Her3
- (2015) Sang Min Lim et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Identification and Characterization of an Irreversible Inhibitor of CDK2
- (2015) Elizabeth Anscombe et al. CHEMISTRY & BIOLOGY
- Designing Irreversible Inhibitors-Worth the Effort?
- (2015) Concepción González-Bello ChemMedChem
- FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
- (2015) R. A. de Claro et al. CLINICAL CANCER RESEARCH
- Development of Selective Covalent Janus Kinase 3 Inhibitors
- (2015) Li Tan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Prolonged and tunable residence time using reversible covalent kinase inhibitors
- (2015) J Michael Bradshaw et al. Nature Chemical Biology
- The ins and outs of selective kinase inhibitor development
- (2015) Susanne Müller et al. Nature Chemical Biology
- Ainsliadimer A selectively inhibits IKKα/β by covalently binding a conserved cysteine
- (2015) Ting Dong et al. Nature Communications
- First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
- (2015) M. Hagel et al. Cancer Discovery
- Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
- (2015) Eric R. Goedken et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Selective Inhibition of Mutant Ras Protein through Covalent Binding
- (2014) Joachim Rudolph et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Activation of Inflammasomes by Agents Causing Idiosyncratic Skin Reactions: A Possible Biomarker
- (2014) J. Kyle Weston et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes
- (2014) Matthias Gehringer et al. ChemMedChem
- Recently targeted kinases and their inhibitors—the path to clinical trials
- (2014) Stefan Knapp et al. CURRENT OPINION IN PHARMACOLOGY
- Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
- (2014) M. Raymond V. Finlay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis
- (2014) Shyam Krishnan et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
- (2014) Nicholas Kwiatkowski et al. NATURE
- A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
- (2014) Apirat Chaikuad et al. Nature Chemical Biology
- A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
- (2014) Bryan R Lanning et al. Nature Chemical Biology
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
- (2014) Li Tan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- (2013) Qingsong Liu et al. CHEMISTRY & BIOLOGY
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases
- (2013) Navasona Krishnan et al. FEBS Journal
- Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα
- (2013) Mariana Nacht et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Toxicity Risk Index, An Index for Warning Idiosyncratic Drug Toxicity
- (2013) Miyoshi Morimoto et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors
- (2013) Rand M. Miller et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
- (2013) A. O. Walter et al. Cancer Discovery
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
- (2012) Martin Schuler et al. BREAST CANCER RESEARCH AND TREATMENT
- Discovery of Potent and Selective Covalent Inhibitors of JNK
- (2012) Tinghu Zhang et al. CHEMISTRY & BIOLOGY
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
- (2012) Iana M Serafimova et al. Nature Chemical Biology
- Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species
- (2011) Vipul Kumar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors
- (2011) Emeline Leproult et al. JOURNAL OF MEDICINAL CHEMISTRY
- Irreversible Nek2 Kinase Inhibitors with Cellular Activity
- (2011) Jeffrey C. Henise et al. JOURNAL OF MEDICINAL CHEMISTRY
- Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity
- (2011) Candice E Paulsen et al. Nature Chemical Biology
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- In Vivo Efficacy of Natural Product-Inspired Irreversible Kinase Inhibitors
- (2010) Sofia Barluenga et al. CHEMBIOCHEM
- A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
- (2010) Wenjun Zhou et al. CHEMISTRY & BIOLOGY
- The (un)targeted cancer kinome
- (2010) Oleg Fedorov et al. Nature Chemical Biology
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemical Modification of Proteins at Cysteine: Opportunities in Chemistry and Biology
- (2009) Justin M. Chalker et al. Chemistry-An Asian Journal
- A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding
- (2009) S. Nakayama et al. DRUG METABOLISM AND DISPOSITION
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- Molecular modeling and crystal structure of ERK2–hypothemycin complexes
- (2008) Giulio Rastelli et al. JOURNAL OF STRUCTURAL BIOLOGY
- 17-Acetoxyjolkinolide B irreversibly inhibits IκB kinase and induces apoptosis of tumor cells
- (2008) Shou-Sheng Yan et al. MOLECULAR CANCER THERAPEUTICS
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- Idiosyncratic Drug Reactions: Past, Present, and Future
- (2007) Jack Uetrecht CHEMICAL RESEARCH IN TOXICOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started